Abstract
The objective of this work was to set up a method to formulate a complex for the assessment of myocardial infarction in vivo. Labetalol was successfully labeled with 99mTc using SnCl2·2H2O as reducing agent. Various reaction parameters were investigated to optimize the labeling yield. The labeled complex was stable for up to 24 h. The heart uptake was 35.5 % ID/Organ at 5 min post-injection, while the clearance pathways from the body behave via both the hepatobiliary and renal routes.
Similar content being viewed by others
References
Halprin S, Frishman W, Kirschner M, Strom J (1980) Am Heart J 99:388–396
Richards D, Tuckman J, Prichard B (1976) Br J Clin Pharmacol 3:849–855
Riva E, Mennini T, Latini R (1991) Br J Pharmacol 104:823–828
Xiao C, Zhou C, Atlas G, Delphin E, Hong YJ (2008) J Brain Res 1198:34–43
Chhabra N, Aseri M, Padmanabhan D (2013) Int J Appl Basic Med Res 3:16–18
Greenslade F, Tobia A, Madison S (1979) Mol Cell Cardiol 11:803–811
Baker J, Hill S, Summers R (2011) Trends Pharmacol Sci 32:227–234
Baker J (2005) Br J Pharmacol 144:317–322
Molenaar P, Parsonage W (2005) Trends Pharmacol Sci 26:368–375
Kaumanna A, Molenaar P (2008) Pharmacol Ther 118:303–336
Molenaar P, Savarimuthu S, Sarsero D, Chen L, Semmler A, Carle A, Yang I, Bartel S, Vetter D, Beyerdörfer I, Krause E, Kaumann A (2007) Naunyn Schmiedebergs Arch Pharmacol 375:11–28
Michel M, Harding S, Bond R (2011) Br J Pharmacol 162:817–822
Castellano M, Böhm M (1997) Hypertension 29:715–722
Yamada S, Ohkura T, Uchida S, Inabe K, Iwatani Y, Kimura R, Hoshino T, Kaburagi T (1996) Life Sci 58:1737–1744
Pinelli A, Trivulzio S, Tomasoni L, Brenna S, Bonacina E, Accinni R (2004) Eur J Pharm Sci 23:277–285
Brodde O, Zerkowski H, Doetsch N, Motomura S, Khamssi M, Michel M (1989) J Am Coll Cardiol 14:323–331
Brodde O, Bruck H, Leineweber K (2006) J Pharmacol Sci 100:323–337
Brodde O, Bruck H, Leineweber K, Seyfarth T (2001) Basic Res Cardiol 96:528–538
Anthonio R, Brodde O, van Veldhuisen D, Scholtens E, Crijns H, van Gilst W (2000) Int J Cardiol 72:137–141
Korkmaz O, Saraç B, Göksel S, Yildirim S, Berkan O (2015) Bagcivan. J Thorac Cardiovasc Surg 149:1036–1040
Law M, Wagner S, Kopka K, Rennera C, Pike V, Schober O, Schäfers M (2010) Nucl Med Biol 37:517–526
Motaleb M, Moustapha M, Ibrahim I (2011) J Radioanal Nucl Chem 289:239–245
Pike V, Law M, Osman S, Davenport R, Rimordi O, Giardina D, Camici P (2000) Pharm Acta Helv 74:191–200
Kopka K, Law M, Breyholz H, Faust A, Höltke C, Riemann B, Schober O (2005) Curr Med Chem 12:2057–2074
Swidan M, Sakr T, Motaleb M, Abd El-Bary A, El-Kolaly M (2014) J Label Compd Radiopharm 57:593–599
Sanad M, Borai E, Fouzy A (2014) J Environ Sci Toxicol Food Technol 8:10–17
Amin A, Abd El-bary A, Abd El-Mohty A, Shokry M, El-Sharawy D (2013) J Nat Sci 5:526–531
Saha GB (2004) The fundamentals of nuclear pharmacy, 5th edn. Springer, New York
Acknowledgments
This project was supported by the Deanship of Scientific Research at Prince Sattam bin Abdulaziz University under the research project # 2015/01/3733.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moustapha, M.E., Motaleb, M.A. & Sanad, M.H. Synthesis and biological evaluation of 99mTc-labetalol for β1-adrenoceptor-mediated cardiac imaging. J Radioanal Nucl Chem 309, 511–516 (2016). https://doi.org/10.1007/s10967-015-4622-3
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10967-015-4622-3